Complete financial analysis of Humacyte, Inc. (HUMAW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humacyte, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hitachi Transport System, Ltd. (9086.T) Income Statement Analysis – Financial Results
- Korea Gas Corporation (036460.KS) Income Statement Analysis – Financial Results
- Trophy Resources, Inc. (TRSI) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (0Q1F.L) Income Statement Analysis – Financial Results
- Maharashtra Scooters Ltd. (MAHSCOOTER.NS) Income Statement Analysis – Financial Results
Humacyte, Inc. (HUMAW)
Industry: Biotechnology
Sector: Healthcare
About Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 1.57M | 1.26M | 1.49M | 6.19M |
| Cost of Revenue | 76.55M | 8.26M | 49.00K | 8.43M | 75.60M |
| Gross Profit | -76.55M | -6.69M | 1.21M | -6.94M | -69.42M |
| Gross Profit Ratio | 0.00% | -427.48% | 96.12% | -465.53% | -1,121.97% |
| Research & Development | 76.55M | 63.26M | 61.34M | 54.08M | 75.60M |
| General & Administrative | 23.39M | 22.88M | 21.13M | 12.01M | 16.27M |
| Selling & Marketing | -3.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.39M | 22.88M | 21.13M | 12.01M | 16.27M |
| Other Expenses | -73.44M | -1.57M | -1.26M | -1.49M | 0.00 |
| Operating Expenses | 23.50M | 84.58M | 81.21M | 64.60M | 16.28M |
| Cost & Expenses | 100.05M | 84.58M | 81.21M | 64.60M | 91.88M |
| Interest Income | 0.00 | 2.63M | 16.00K | 278.00K | 269.00K |
| Interest Expense | 1.13M | 6.20M | 4.35M | 2.20M | 2.30M |
| Depreciation & Amortization | 7.72M | 8.26M | 8.28M | 8.43M | 6.75M |
| EBITDA | -96.46M | 2.49M | -72.97M | -56.25M | -78.94M |
| EBITDA Ratio | 0.00% | -10,245.69% | -10,845.61% | -3,753.92% | -1,275.93% |
| Operating Income | -100.05M | -84.58M | -81.21M | -64.60M | -85.69M |
| Operating Income Ratio | 0.00% | -5,404.35% | -6,429.77% | -4,332.66% | -1,385.02% |
| Total Other Income/Expenses | -10.73M | 72.61M | 54.73M | -1.92M | 269.00K |
| Income Before Tax | -110.78M | -11.97M | -26.48M | -66.52M | -85.42M |
| Income Before Tax Ratio | 0.00% | -764.54% | -2,096.36% | -4,461.70% | -1,380.67% |
| Income Tax Expense | 0.00 | -76.18M | -64.01M | 2.20M | 0.00 |
| Net Income | -110.78M | 64.22M | 37.54M | -68.73M | -85.42M |
| Net Income Ratio | 0.00% | 4,103.45% | 2,971.97% | -4,609.39% | -1,380.67% |
| EPS | -1.07 | 0.62 | 0.94 | -5.52 | -4.25 |
| EPS Diluted | -1.07 | 0.62 | 0.94 | -5.52 | -4.25 |
| Weighted Avg Shares Out | 103.42M | 103.05M | 39.97M | 12.45M | 20.12M |
| Weighted Avg Shares Out (Dil) | 103.42M | 103.05M | 39.97M | 12.45M | 20.12M |
Source: https://incomestatements.info
Category: Stock Reports